



PRESS RELEASE

Moberg Pharma's Interim report for January – September 2021 to be published on November 9 - Invitation to teleconference

STOCKHOLM, November 2nd, 2021 – On November 9th, 2021, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Interim report for January – September 2021. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.

The teleconference will be hosted by Moberg Pharmas's CEO Anna Ljung and VP Finance Mark Beveridge. The presentation will be held in English.

Date: November 9th, 2021
Time: 3:00 pm (CET)

To participate in the conference, please dial in on any number below before the start of the call:

SE: +46 8 505 583 57
US: +1 646 722 49 57

The quarterly report and other information material will be made public on:
<http://www.mobergpharma.com/investors/calendarpresentations>

For additional information, please contact:

Anna Ljung, CEO, Phone: + 46 70 766 60 30, e-post: anna.ljung@mobergpharma.se
Mark Beveridge, VP Finance, Phone: + 46 76 805 82 88, e-post: mark.beveridge@mobergpharma.se

About Moberg Pharma, www.mobergpharma.com

Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's main asset, MOB-015, is a novel topical treatment for onychomycosis. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in Europe and Japan, among others, and the company's intention is to submit a registration application during the second half of 2021 in Europe. Moberg Pharma is headquartered in Stockholm and the company's shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).